Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206052 | 1.00 | CPN1 (0.39) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL149567 | 0.98 | SLC6A2 (0.40) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17311067 | 0.86 | — | — | |
| SCHEMBL2095890 | 0.86 | — | — | |
| SCHEMBL17311156 | 0.86 | — | — | |
| SCHEMBL149437 | 0.82 | CPN1 (0.37) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL149436 | 0.82 | CPN1 (0.37) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL140296 | 0.82 | — | — | |
| SCHEMBL8056802 | 0.82 | — | — | |
| SCHEMBL16712669 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111372587-B | ENPP1 inhibitors and their use for the treatment of cancer | 里兰斯坦福初级大学理事会 | 2024-01-09 | — | — | CN | disclosed |
| CN-110392678-B | Compounds and methods for IDO and TDO modulation, and indications therefor | 普莱希科公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-102584816-B | Method for preparing polycycle tertiary amine | UNIV EAST CHINA SCIENCE & TECH | 2014-07-30 | — | — | CN | disclosed |
| CN-102584816-A | Method for preparing polycycle tertiary amine | UNIV EAST CHINA SCIENCE & TECH | 2012-07-18 | — | — | CN | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-0666850-B1 | 1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8aBETA)-6-ISOQUINOLINEAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | FOURNIER IND & SANTE (FR) | 1997-02-05 | — | — | EP | disclosed |
| EP-0699187-B1 | BETA,BETA-DIMETHYL-4-PIPERIDINEETHANAMINE DERIVATIVES AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS | FOURNIER IND & SANTE (FR) | 1997-01-22 | — | — | EP | disclosed |
| US-5580881-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; FUNGICIDES; 2,3-EPOXYSQUALENE CYCLASE INHIBITORS | FOURNIER INDUSTRIE ET SANTE (FR) | 1996-12-03 | — | — | US | disclosed |
| EP-0468457-B1 | Novel substituted piperidines and their use as inhibitors of cholesterol synthesis | MERRELL DOW PHARMA (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0666850-A1 | 1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8a-g(b))-6-ISOQUINOLINEAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF. | FOURNIER IND & SANTE (FR) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994026713-A1 | DERIVATIVES OF β, β-DIMETHYL-4-PIPERIDINEETHANAMINE AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS | FOURNIER INDUSTRIE ET SANTE (FR) | 1994-11-24 | — | — | WO | disclosed |
| EP-0468457-A1 | Novel substituted piperidines and their use as inhibitors of cholesterol synthesis | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | CPN1 3035/4885CPB2 3422/4885SLC6A2 2595/4885 |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | CPN1 3592/4885CPB2 1592/4885SLC6A2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.